All Stories

  1. Post-Licensure Safety of Nirsevimab from the Canadian National Vaccine Safety (CANVAS) Network
  2. Using behavioural science to improve antibiotic stewardship in Canadian long-term care homes: Protocol for a multi-center cluster randomized quality improvement study
  3. SARS-CoV-2 burden on the floor was associated with COVID-19 cases and outbreaks in two acute care hospitals: a prospective cohort study
  4. Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study
  5. Assessing a safety climate tool adapted to address respiratory illnesses in Canadian hospitals
  6. Use of whole genome sequencing to identify low‐frequency mutations in SARS‐CoV‐2 patients treated with remdesivir
  7. Natural Language Processing for Clinical Laboratory Data Repository Systems: Implementation and Evaluation for Respiratory Viruses
  8. The epidemiology and healthcare costs of community-acquired pneumonia in Ontario, Canada: a population-based cohort study
  9. Natural Language Processing for Clinical Laboratory Data Repository Systems: Implementation and Evaluation for Respiratory Viruses (Preprint)
  10. Use of whole genome sequencing to identify low-frequency mutations in COVID-19 patients treated with remdesivir
  11. Severity of Omicron SARS-CoV-2 Infection in Vaccinated and Unvaccinated Residents of Long Term Care Homes
  12. Burden of severe illness associated with laboratory confirmed influenza in adults aged 50–64 years: A rapid review
  13. Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers: Results of a prospective cohort study
  14. Frequency of hand hygiene opportunities in patients on a general surgery service
  15. Evidence of transmission of Clostridium difficile in asymptomatic patients following admission screening in a tertiary care hospital
  16. N o 225-Lignes directrices quant à la prise en charge des patientes en obstétrique chez lesquelles la présence du syndrome respiratoire aigu sévère (SRAS) est soupçonnée ou probable, et des nouveau-nés issus de ces patientes
  17. No. 225-Management Guidelines for Obstetric Patients and Neonates Born to Mothers With Suspected or Probable Severe Acute Respiratory Syndrome (SARS)
  18. Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study
  19. Phylogenetic analysis of emergent Streptococcus pneumoniae serotype 22F causing invasive pneumococcal disease using whole genome sequencing
  20. Pre-and post-pandemic trends in antiviral use in hospitalized patients with laboratory-confirmed influenza: 2004/05–2013/14, Toronto, Canada
  21. Detecting and quantifying influenza virus with self- versus investigator-collected mid-turbinate nasal swabs
  22. Optimal hand washing technique to minimize bacterial contamination before neuraxial anesthesia: a randomized control trial
  23. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
  24. Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients
  25. Active Surveillance for Influenza Reduces but Does Not Eliminate Hospital Exposure to Patients With Influenza
  26. Influenza and rhinovirus viral load and disease severity in upper respiratory tract infections
  27. Rapid Emergence of a New Clone Impacts the Population at Risk and Increases the Incidence of Type emm89 Group A Streptococcus Invasive Disease
  28. Unit-Specific Rates of Hand Hygiene Opportunities in an Acute-Care Hospital
  29. High Incidence of Invasive group A Streptococcal Infections in Remote Indigenous Communities in Northwestern Ontario, Canada.
  30. Serotype Distribution, Population Structure, and Antimicrobial Resistance of Group B Streptococcus Strains Recovered from Colonized Pregnant Women
  31. Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for RecurrentClostridium difficileInfection: An Open-Label, Randomized Controlled Trial
  32. Community- and Healthcare-Associated Methicillin-Resistant Staphylococcus aureus Strains: An Investigation Into Household Transmission, Risk Factors, and Environmental Contamination
  33. Acquisition of bacteria on health care workers' hands after contact with patient privacy curtains
  34. Capsular Switching and Other Large-Scale Recombination Events in Invasive Sequence Type 1 Group BStreptococcus
  35. Predictors of influenza among older adults in the emergency department
  36. The Effect of Hospital Isolation Precautions on Patient Outcomes and Cost of Care: A Multi-Site, Retrospective, Propensity Score-Matched Cohort Study
  37. Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study
  38. Clonal Complex 17 Group B Streptococcus strains causing invasive disease in neonates and adults originate from the same genetic pool
  39. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis
  40. Association of serotype with respiratory presentations of pneumococcal infection, Ontario, Canada, 2003–2011
  41. Determinants of Outcome in Hospitalized Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: Results From National Surveillance in Canada, 2008-2012
  42. Antimicrobial surfaces to prevent healthcare-associated infections: a systematic review
  43. What Is the Appropriate Meropenem MIC for Screening of Carbapenemase-Producing Enterobacteriaceae in Low-Prevalence Settings?
  44. Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers
  45. High Incidence of Invasive Group A Streptococcus Disease Caused by Strains of UncommonemmTypes in Thunder Bay, Ontario, Canada
  46. Vancomycin-Variable Enterococcal Bacteremia
  47. Epidemiological features of influenza in Canadian adult intensive care unit patients
  48. Acceptance of intradermal inactivated influenza vaccines among hospital staff following 2 seasonal vaccination campaigns
  49. Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs
  50. Factors Associated With Complications of Clostridium difficile Infection in a Multicenter Prospective Cohort
  51. Emergence of Serotype IV Group B Streptococcus Adult Invasive Disease in Manitoba and Saskatchewan, Canada, Is Driven by Clonal Sequence Type 459 Strains
  52. Examining Perceptions about Mandatory Influenza Vaccination of Healthcare Workers through Online Comments on News Stories
  53. Is the prevalence of antibiotic-resistant organisms changing in Canadian hospitals? Comparison of point-prevalence survey results in 2010 and 2012
  54. Sequence type 1 group B Streptococcus , an emerging cause of invasive disease in adults, evolves by small genetic changes
  55. Middle East respiratory syndrome
  56. Population Structure and Antimicrobial Resistance of Invasive Serotype IV Group B Streptococcus , Toronto, Ontario, Canada
  57. Infectious Complications Following Transrectal Ultrasound-guided Prostate Biopsy: A Canadian Tertiary Cancer Center Experience
  58. Simulation Study of the Effect of Influenza and Influenza Vaccination on Risk of Acquiring Guillain-Barré Syndrome
  59. Protecting the Frontline: Designing an Infection Prevention Platform for Preventing Emerging Respiratory Viral Illnesses in Healthcare Personnel
  60. Zanamivir versus trivalent split virus influenza vaccine: a pilot randomized trial
  61. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: A cluster randomized trial
  62. Vancomycin-Variable Enterococci Can Give Rise to Constitutive Resistance during Antibiotic Therapy
  63. Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study
  64. Reply to Vanhems et al
  65. In Vitro Activity of New Cephalosporins vs Streptococcus pneumoniae from the Canadian Bacterial Surveillance Network: 2008–2011
  66. Previous Antibiotic Exposure and Antimicrobial Resistance in Invasive Pneumococcal Disease: Results From Prospective Surveillance
  67. External cues to action and influenza vaccination among post-graduate trainee physicians in Toronto, Canada
  68. Reply to Chironda et al
  69. Health care workers, mandatory influenza vaccination policies and the law
  70. A Systematic and Functional Classification of Streptococcus pyogenes That Serves as a New Tool for Molecular Typing and Vaccine Development
  71. The integration of barcode scanning technology into Canadian public health immunization settings
  72. Influenza vaccination and Guillain-Barré syndrome
  73. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
  74. Evolutionary pathway to increased virulence and epidemic group A Streptococcus disease derived from 3,615 genome sequences
  75. The Reemergence of Severe Group A Streptococcal Disease: an Evolutionary Perspective
  76. Medusa's Ugly Head Again: From SARS to MERS-CoV
  77. Rate of Healthcare Worker–Patient Interaction and Hand Hygiene Opportunities in an Acute Care Setting
  78. Reducing Antimicrobial Therapy for Asymptomatic Bacteriuria Among Noncatheterized Inpatients: A Proof-of-Concept Study
  79. Characterization of Invasive Group B Streptococcus Strains from the Greater Toronto Area, Canada
  80. Outbreak of Vancomycin-Susceptible Enterococcus faecium Containing the Wild-Type vanA Gene
  81. Vancomycin-Variable Enterococcus faecium: In Vivo Emergence of Vancomycin Resistance in a Vancomycin-Susceptible Isolate
  82. Peripartum outcomes: non-adjuvanted v. adjuvanted H1N1 vaccination
  83. Healthcare-Associated Influenza in Canadian Hospitals from 2006 to 2012
  84. Trends in antiviral therapy of adults hospitalized with influenza in Canada since the end of the 2009 pandemic
  85. Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole
  86. The Effect of Gowning on Labor Epidural Catheter Colonization Rate
  87. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995–2011
  88. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012
  89. Complete sequences of a novel blaNDM-1-harbouring plasmid from Providencia rettgeri and an FII-type plasmid from Klebsiella pneumoniae identified in Canada
  90. Understanding the burden of influenza infection among adults in Canadian hospitals: A comparison of the 2009-2010 pandemic season with the prepandemic and postpandemic seasons
  91. In Memoriam
  92. Downstream Impact of Urine Cultures Ordered without Indication at Two Acute Care Teaching Hospitals
  93. Epidemiology and Outcome of Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus (MRSA) in Canadian Hospitals
  94. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study
  95. Hospital Outbreak of Middle East Respiratory Syndrome Coronavirus
  96. Indeterminate tcdB using a Clostridium difficile PCR assay: a retrospective cohort study
  97. Prevalence of Colonization and Infection with Methicillin-ResistantStaphylococcus aureusand Vancomycin-ResistantEnterococcusand ofClostridium difficileInfection in Canadian Hospitals
  98. The Occurrence and Impact of Bacterial Organisms Complicating Critical Care Illness Associated With 2009 Influenza A(H1N1) Infection
  99. Contamination of Canadian private drinking water sources with antimicrobial resistant Escherichia coli
  100. Have changing pneumococcal vaccination programmes impacted disease in Ontario?
  101. Efficacy of Admission Screening for Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae
  102. Cardiac complications of influenza infection in 3 adults
  103. Measuring influenza immunization coverage among health care workers in acute care hospitals and continuing care organizations in Canada
  104. Risk Factors for Influenza among Health Care Workers during 2009 Pandemic, Toronto, Ontario, Canada
  105. Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009
  106. Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant
  107. Behind the mask: Determinants of nurse's adherence to facial protective equipment
  108. An observational study of the hand hygiene initiative: a comparison of preintervention and postintervention outcomes
  109. Statistical estimates of respiratory admissions attributable to seasonal and pandemic influenza for Canada
  110. Disparity in infection control practices for multidrug-resistant Enterobacteriaceae
  111. Maternal Antibiotic Exposure and Risk of Antibiotic Resistance in Neonatal Early-onset Sepsis
  112. Laboratory-Confirmed Pandemic H1N1 Influenza in Hospitalized Adults: Findings from the Canadian Nosocomial Infections Surveillance Program, 2009-2010
  113. Outbreak of Carbapenem-Resistant Enterobacteriaceae Containing blaNDM-1, Ontario, Canada
  114. The Impact of Infection on Population Health: Results of the Ontario Burden of Infectious Diseases Study
  115. A randomized control trial comparing immunogenicity, safety, and preference for self- versus nurse-administered intradermal influenza vaccine
  116. The Social Determinants of Health and Pandemic H1N1 2009 Influenza Severity
  117. Prevalence and predictors of MRSA, ESBL, and VRE colonization in the ambulatory IBD population
  118. Outbreak of Extended-Spectrum β-Lactamase–producing Klebsiella oxytoca Infections Associated with Contaminated Handwashing Sinks1
  119. Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010
  120. Short and Long-Term Safety of the 2009 AS03-Adjuvanted Pandemic Vaccine
  121. In Vitro Activity Of Ceftaroline And Comparative Agents Against Clinical Isolates Of Streptococcus Pneumoniae Collected From An Ongoing Canada Wide Surveillance Program: 2008 - 2011
  122. Decreased Susceptibility to Noncarbapenem Antimicrobials in Extended-Spectrum-β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolates in Toronto, Canada
  123. Emergency department visits and infections
  124. Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP)
  125. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy a...
  126. Risk of infection following a visit to the emergency department: a cohort study
  127. Seroprevalence of Pandemic Influenza H1N1 in Ontario from January 2009–May 2010
  128. Incidence of Influenza in Healthy Adults and Healthcare Workers: A Systematic Review and Meta-Analysis
  129. Another Look at the Human Papillomavirus Vaccine Experience in Canada
  130. Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study
  131. H1N1 in Pregnancy: A Tertiary Care Centre Experience
  132. Self-Collected Mid-Turbinate Swabs for the Detection of Respiratory Viruses in Adults with Acute Respiratory Illnesses
  133. The role of drinking water in the transmission of antimicrobial-resistant E. coli
  134. Evaluation of Coseasonality of Influenza and Invasive Pneumococcal Disease: Results from Prospective Surveillance
  135. Susceptibility ofStreptococcus pneumoniaeto Fluoroquinolones in Canada
  136. New Delhi metallo- -lactamase-1: local acquisition in Ontario, Canada, and challenges in detection
  137. A Comparison Of The First And Second Waves Of H1N1-Related Critical Illness In Canada
  138. Prevalent And Incident Bacterial Infections Among Canadian Critically Ill Patients With Influenza A (H1N1) 2009- Preliminary Data
  139. Respiratory illnesses in Canadian health care workers: a pilot study of influenza vaccine and oseltamivir prophylaxis during the 2007/2008 influenza season
  140. Infection prevention and control practices related to Clostridium difficile infection in Canadian acute and long-term care institutions
  141. Systemic Dysregulation of Angiopoietin-1 and -2 in Streptococcal Toxic Shock Syndrome
  142. Distribution of Antiseptic Resistance GenesqacA, qacB, andsmrin Methicillin-Resistant Staphylococcus aureus Isolated in Toronto, Canada, from 2005 to 2009
  143. Novel Mutations in a Patient Isolate of Streptococcus agalactiae with Reduced Penicillin Susceptibility Emerging after Long-Term Oral Suppressive Therapy
  144. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness
  145. Effect of Patterns of Transferring Patients among Healthcare Institutions on Rates of Nosocomial Methicillin-Resistant Staphylococcus aureus Transmission: A Monte Carlo Simulation
  146. New Delhi metallo- -lactamase-1 in Enterobacteriaceae: emerging resistance
  147. 644: Knowledge about H1N1 influenza and the vaccine impacts vaccination uptake among pregnant women
  148. When should a diagnosis of influenza be considered in adults requiring intensive care unit admission? Results of population-based active surveillance in Toronto
  149. Predictors of pandemic influenza infection in adults presenting to two urban emergency departments, Toronto, 2009
  150. Epidemic of Group A Streptococcus M/ emm 59 Causing Invasive Disease in Canada
  151. Respiratory Virus Infection and Risk of Invasive Meningococcal Disease in Central Ontario, Canada
  152. Pandemic (H1N1) 2009: assessing the response
  153. Physicians and hand hygiene practice: a focus group study
  154. Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience
  155. Compulsory School-Entry Vaccination Laws and Exemptions: Who Is Opting Out in Ontario and Why Does It Matter?
  156. Risk Factors for SARS Transmission from Patients Requiring Intubation: A Multicentre Investigation in Toronto, Canada
  157. Epidemiology of influenza-associated hospitalization in adults, Toronto, 2007/8
  158. Economic Appraisal of Ontario's Universal Influenza Immunization Program: A Cost-Utility Analysis
  159. Laboratory diagnosis of 2009 H1N1 influenza A virus
  160. Methicillin-Resistant Staphylococcus aureus Colonization or Infection in Canada: National Surveillance and Changing Epidemiology, 1995–2007
  161. Hypervirulent Clostridium difficile Strains in Hospitalized Patients, Canada1
  162. Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates
  163. Photonic Sensors: Towards the Photonic Nose: A Novel Platform for Molecule and Bacteria Identification (Adv. Mater. 12/2010)
  164. Review: Extended-duration chemoprophylaxis with neuraminidase inhibitors prevents symptomatic influenza
  165. Antimicrobial Susceptibilities of Health Care-Associated and Community-Associated Strains of Methicillin-Resistant Staphylococcus aureus from Hospitalized Patients in Canada, 1995 to 2008
  166. Evaluation of Pneumonia Severity and Acute Physiology Scores to Predict ICU Admission and Mortality in Patients Hospitalized for Influenza
  167. Molecular complexity of successive bacterial epidemics deconvoluted by comparative pathogenomics
  168. Focus Group Study of Hand Hygiene Practice among Healthcare Workers in a Teaching Hospital in Toronto, Canada
  169. Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada
  170. Health Care–Associated Clostridium difficile Infection in Canada: Patient Age and Infecting Strain Type Are Highly Predictive of Severe Outcome and Mortality
  171. High Prevalence of ST131 Isolates Producing CTX-M-15 and CTX-M-14 among Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates from Canada
  172. Decreased necrotizing fasciitis capacity caused by a single nucleotide mutation that alters a multiple gene virulence axis
  173. Is a Mass Immunization Program for Pandemic (H1N1) 2009 Good Value for Money? Early Evidence from the Canadian Experience.
  174. Pneumococcal Pneumonia: Potential for Diagnosis through a Urinary Metabolic Profile
  175. Detection and Characterization of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates in Canada: Results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006
  176. Towards the Photonic Nose: A Novel Platform for Molecule and Bacteria Identification
  177. Assessing the Impact of Intravenous Immunoglobulin in the Management of Streptococcal Toxic Shock Syndrome: A Noble but Difficult Quest
  178. Population-Based Surveillance for Invasive Pneumococcal Disease in Homeless Adults in Toronto
  179. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults ≥65 years of age
  180. Infection with H274Y-positive influenza A (H1N1) is not associated with a change in nasopharyngeal Streptococcus pneumoniae colonization in patients
  181. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008
  182. Characterization of Cefoxitin-Resistant Escherichia coli Isolates from Recreational Beaches and Private Drinking Water in Canada between 2004 and 2006
  183. Influenza estacional en adultos y niños—Diagnóstico, tratamiento, quimioprofilaxis y control de brotes institucionales: Guías de práctica clínica de la Sociedad de Enfermedades Infecciosas de Estados Unidos de América
  184. Seasonal Influenza in Adults and Children—Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America
  185. Lignes directrices quant à la prise en charge des patientes en obstétrique chez lesquelles la présence du syndrome respiratoire aigu sévère (SRAS) est soupçonnée ou probable, et des nouveau-nés issus de ces patientes
  186. Management Guidelines for Obstetric Patients and Neonates Born to Mothers With Suspected or Probable Severe Acute Respiratory Syndrome (SARS)
  187. Health Care–Associated Clostridium difficile Infection in Adults Admitted to Acute Care Hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program Study
  188. Impact of a Mandatory Infection Control Education Program on Nosocomial Acquisition of Methicillin-ResistantStaphylococcus aureus
  189. Infection control practices related to Clostridium difficile infection in acute care hospitals in Canada
  190. CME Questions
  191. Diagnostic Testing or Empirical Therapy for Patients Hospitalized with Suspected Influenza: What to Do?
  192. Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae
  193. The Effect of Universal Influenza Immunization on Mortality and Health Care Use
  194. The individual, environmental, and organizational factors that influence nurses' use of facial protection to prevent occupational transmission of communicable respiratory illness in acute care hospitals
  195. Characterization of Clostridium difficile Strains Isolated from Patients in Ontario, Canada, from 2004 to 2006
  196. Antimalarial Therapy Selection for Quinolone Resistance among Escherichia coli in the Absence of Quinolone Exposure, in Tropical South America
  197. Risk Factors for Methicillin-Resistant Staphylococcus aureus (MRSA) Acquisition in Roommate Contacts of Patients Colonized or Infected With MRSA in an Acute-Care Hospital
  198. Dietary Intake of Elderly Living In Toronto Long-Term Care Facilities: Comparison with the Dietary Reference Intake: Response to Klevay
  199. Reply to Chan‐Tack and Murray
  200. Factors Associated With Acquisition of Vancomycin-Resistant Enterococci (VRE) in Roommate Contacts of Patients Colonized or Infected with VRE in a Tertiary Care Hospital
  201. A Cross-Sectional Study of Maternity Care Providers’ and Women’s Knowledge, Attitudes, and Behaviours Towards Influenza Vaccination During Pregnancy
  202. At the Threshold: Defining Clinically Meaningful Resistance Thresholds for Antibiotic Choice in Community‐Acquired Pneumonia
  203. Impact of public vaccination programs on adult vaccination rates: Two examples from Ontario, Canada
  204. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance
  205. Neonatal group B streptococcal disease: Incidence, presentation, and mortality
  206. Antiviral Therapy and Outcomes of Influenza Requiring Hospitalization in Ontario, Canada
  207. Antivirals and the Control of Influenza Outbreaks
  208. Factors Associated With Critical-Care Healthcare Workers' Adherence to Recommended Barrier Precautions During the Toronto Severe Acute Respiratory Syndrome Outbreak
  209. Dietary Intake of Elderly Living in Toronto Long-Term Care Facilities: Comparison to the Dietary Reference Intake
  210. Mupirocin-Resistant, Methicillin-Resistant Staphylococcus aureus Strains in Canadian Hospitals
  211. RESPONSE LETTER TO DR. HEMILÄ
  212. Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome
  213. ampC gene expression in promoter mutants of cefoxitin-resistant Escherichia coli clinical isolates
  214. Invasive Pneumococcal Disease in Solid Organ Transplant Recipients?10-Year Prospective Population Surveillance
  215. Comparative Genomics of Canadian Epidemic Lineages of Methicillin-Resistant Staphylococcus aureus
  216. Severe Acute Respiratory Syndrome (SARS) Coronavirus
  217. Adverse Events Associated with High-Dose Ribavirin: Evidence from the Toronto Outbreak of Severe Acute Respiratory Syndrome
  218. Alternative Methods of Estimating an Incubation Distribution
  219. Randomized Controlled Trial of Chlorhexidine Gluconate for Washing, Intranasal Mupirocin, and Rifampin and Doxycycline Versus No Treatment for the Eradication of Methicillin-Resistant Staphylococcus aureus Colonization
  220. Appropriate measures of influenza immunization program effectiveness
  221. Effect of Multivitamin and Mineral Supplementation on Episodes of Infection in Nursing Home Residents: A Randomized, Placebo-Controlled Study
  222. Guillain-Barré Syndrome After Influenza Vaccination in Adults
  223. Verification of the IDI-MRSA Assay for Detecting Methicillin-Resistant Staphylococcus aureus in Diverse Specimen Types in a Core Clinical Laboratory Setting
  224. OVERDIAGNOSIS OF ASTHMA AND ITS RELATIONSHIP TO BODY MASS INDEX
  225. Macrolide Resistance in Bacteremic Pneumococcal Disease: Implications for Patient Management
  226. Accuracy of Healthcare Worker Recall and Medical Record Review for Identifying Infectious Exposures to Hospitalized Patients
  227. Suspected transmission of methicillin-resistant Staphylococcus aureus between domestic pets and humans in veterinary clinics and in the household
  228. Cluster of Cases of Severe Acute Respiratory Syndrome Among Toronto Healthcare Workers After Implementation of Infection Control Precautions: A Case Series
  229. An outbreak of methicillin-resistant Staphylococcus aureus skin infections resulting from horse to human transmission in a veterinary hospital
  230. Early diagnosis of SARS: lessons from the Toronto SARS outbreak
  231. Methicillin-Resistant Staphylococcus aureus in Canadian Aboriginal People
  232. Febrile respiratory illness in the intensive care unit setting: an infection control perspective
  233. Viable Group A Streptococci in Macrophages during Acute Soft Tissue Infection
  234. Methicillin-resistant Staphylococcus aureus Colonization in Veterinary Personnel
  235. Coordinated Response to SARS, Vancouver, Canada
  236. A survey of physician's attitudes regarding management of severe group A streptococcal infections
  237. Methicillin-resistant Staphylococcus Aureus in Horses at a Veterinary Teaching Hospital: Frequency, Characterization, and Association with Clinical Disease
  238. Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management
  239. Use of a Selective Enrichment Broth To Recover Clostridium difficile from Stool Swabs Stored under Different Conditions
  240. Clinical and Epidemiologic Features of Methicillin-Resistant Staphylococcus aureus in Elderly Hospitalized Patients
  241. Effect of a multifaceted intervention on number of antimicrobial prescriptions for suspected urinary tract infections in residents of nursing homes: cluster randomised controlled trial
  242. Genetic Diversity among Type emm28 Group A Streptococcus Strains Causing Invasive Infections and Pharyngitis
  243. Decreased Prevalence of Virulence Factors among Ciprofloxacin-Resistant Uropathogenic Escherichia coli Isolates
  244. Hospital-Acquired Invasive Group A Streptococcal Infections in Ontario, Canada, 1992-2000
  245. Risk Factors for Pediatric Invasive Group A Streptococcal Disease
  246. Modeling Transmission of Methicillin-Resistant Staphylococcus Aureus Among Patients Admitted to a Hospital
  247. Mosaic Prophages with Horizontally Acquired Genes Account for the Emergence and Diversification of the Globally Disseminated M1T1 Clone of Streptococcus pyogenes
  248. Identification of a Progenitor of the CTX-M-9 Group of Extended-Spectrum β-Lactamases from Kluyvera georgiana Isolated in Guyana
  249. Prevalence and Characterization of Invasive Isolates of Streptococcus pyogenes with Reduced Susceptibility to Fluoroquinolones
  250. Detection of Airborne Severe Acute Respiratory Syndrome (SARS) Coronavirus and Environmental Contamination in SARS Outbreak Units
  251. Predicting Antimicrobial Resistance in Invasive Pneumococcal Infections
  252. Can Routine Laboratory Tests Discriminate between Severe Acute Respiratory Syndrome and Other Causes of Community‐Acquired Pneumonia?
  253. Patient Contact Recall after SARS Exposure
  254. Does isolation prevent the spread of methicillin-resistant Staphylococcus aureus?
  255. Economic Evaluation of Oseltamivir Phosphate for Postexposure Prophylaxis of Influenza in Long-Term Care Facilities
  256. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach
  257. Beliefs and practices of Ontario midwives about influenza immunization
  258. Nosocomial Acquisition of Methicillin-Resistant Staphylococcus aureus During an Outbreak of Severe Acute Respiratory Syndrome
  259. Community-associated methicillin-resistant Staphylococcus aureus in horses and humans who work with horses
  260. Compliance and psychological impact of the quarantine experience during SARS
  261. SARS outbreak in the Greater Toronto Area: the emergency department experience
  262. Adverse Effects of Amantadine and Oseltamivir Used During Respiratory Outbreaks in a Center for Developmentally Disabled Adults
  263. Complete Nucleotide Sequence of a 92-Kilobase Plasmid Harboring the CTX-M-15 Extended-Spectrum Beta-Lactamase Involved in an Outbreak in Long-Term-Care Facilities in Toronto, Canada
  264. In Vitro Antimicrobial Susceptibilities of Streptococcus pneumoniae Clinical Isolates Obtained in Canada in 2002
  265. Health Care Workers and the Initiation of Treatment for Latent Tuberculosis Infection
  266. Enterococcus faecium N03-0072 carries a new VanD-type vancomycin resistance determinant: characterization of the VanD5 operon
  267. Genome-wide molecular dissection of serotype M3 group A Streptococcus strains causing two epidemics of invasive infections
  268. Let Him Who Desires Peace Prepare for War: United States Hospitals and Severe Acute Respiratory Syndrome Preparedness
  269. Clostridium difficile infection in hospitals: a brewing storm
  270. Nursing Home Residents and Enterobacteriaceae Resistant to Third-Generation Cephalosporins
  271. Transmission and control of SARS
  272. SARS in Healthcare Facilities, Toronto and Taiwan
  273. Hospital Preparedness and SARS
  274. Patterns of Handwashing Behavior and Visits to Patients on a General Medical Ward of Healthcare Workers
  275. News in Antimicrobial Resistance: Documenting the Progress of Pathogens
  276. SARS among Critical Care Nurses, Toronto
  277. Facility-Level Correlates of Antimicrobial Use in Nursing Homes
  278. Severe Invasive Group a Streptococcal Infections
  279. Nutrition Risk Factors for Survival in the Elderly Living in Canadian Long-Term Care Facilities
  280. SARS — One Year Later
  281. Use of, Effectiveness of, and Attitudes Regarding Influenza Vaccine Among House Staff
  282. High Heart Rates at Anaerobic Threshold in Healthy Women
  283. Invasive Group A Streptococcal Disease: Risk Factors for Adults
  284. Emergence of Macrolide Resistance in Throat Culture Isolates of Group A Streptococci in Ontario, Canada, in 2001
  285. Antimicrobial Susceptibility Breakpoints and First-Step parC Mutations in Streptococcus pneumoniae : Redefining Fluoroquinolone Resistance
  286. Identification of Severe Acute Respiratory Syndrome in Canada
  287. Is resistance futile?
  288. Clinical manifestations associated with the aberrant expression of the soluble granulocyte-macrophage colony-stimulating factor receptor in patients presenting with haematological malignancies
  289. Clinical and Epidemiologic Features of Group A Streptococcal Pneumonia in Ontario, Canada
  290. Association of Human Leukocyte Antigen with Outcomes of Infectious Diseases: The Streptococcal Experience
  291. Risk Factors for Resistance to Antimicrobial Agents among Nursing Home Residents
  292. Prospective Surveillance for Primary Bloodstream Infections Occurring in Canadian Hemodialysis Units
  293. Microbiologic findings and risk factors for antimicrobial resistance at myringotomy for tympanostomy tube placement—a prospective study of 601 children in Toronto
  294. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections
  295. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections
  296. Prevention of Invasive Group A Streptococcal Disease among Household Contacts of Case Patients and among Postpartum and Postsurgical Patients: Recommendations from the Centers for Disease Control and Prevention
  297. Laboratory Characterization of Methicillin‐Resistant Staphylococcus aureus in Canadian Hospitals: Results of 5 Years of National Surveillance, 1995–1999
  298. Clinical aspects and cost of invasive Streptococcus pneumoniae infections in children: resistant vs. susceptible strains
  299. Laboratory Contamination of Specimens with Quality Control Strains of Vancomycin-Resistant Enterococci in Ontario
  300. Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 2000
  301. Activities of New Fluoroquinolones, Ketolides, and Other Antimicrobials against Blood Culture Isolates of Viridans Group Streptococci from across Canada, 2000
  302. Activity of BMS-284756, a Novel Des-Fluoro(6) Quinolone, against Staphylococcus aureus, Including Contributions of Mutations to Quinolone Resistance
  303. Use of Oseltamivir During Influenza Outbreaks in Ontario Nursing Homes, 1999–2000
  304. Severe Group A Streptococcal Soft-Tissue Infections in Ontario: 1992-1996
  305. Quality and methods of developing practice guidelines
  306. Exploring the Pathogenesis of Necrotizing Fasciitis Due to Streptococcus pneumoniae
  307. Annualized Incidence and Spectrum of Illness from an Outbreak Investigation of Bell’s Palsy
  308. Prevalence and Mechanisms of Macrolide Resistance in Invasive and Noninvasive Group B Streptococcus Isolates from Ontario, Canada
  309. Evidence for Superantigen Involvement in Severe Group A Streptococcal Tissue Infections
  310. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home
  311. Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals
  312. Population-based active surveillance for neonatal group B streptococcal infections in Alberta, Canada: implications for vaccine formulation
  313. A Nosocomial Outbreak of Fluoroquinolone‐Resistant Streptococcus pneumoniae
  314. Identifying research priorities on infections in older adults: proceedings of an interdisciplinary workshop
  315. Antibodies to Capsular Polysaccharides of Group B Streptococcus in Pregnant Canadian Women: Relationship to Colonization Status and Infection in the Neonate
  316. Evaluation of Susceptibility Testing To Detect Fluoroquinolone Resistance Mechanisms in Streptococcus pneumoniae
  317. Antibiotic use in ontario facilities that provide chronic care
  318. Oropharyngeal Candidiasis in Patients with Human Immunodeficiency Virus: Correlation of Clinical Outcome with In Vitro Resistance, Serum Azole Levels, and Immunosuppression
  319. A 2 factor model helped to rule out early stage necrotising fasciitis
  320. A RANDOMIZED TRIAL TO MEASURE THE OPTIMAL ROLE OF THE PHARMACIST IN PROMOTING EVIDENCE-BASED ANTIBIOTIC USE IN ACUTE CARE HOSPITALS
  321. A Blinded Comparison of Three Laboratory Protocols for the Identification of Patients Colonized With Methicillin-Resistant Staphylococcus aureus
  322. Development of Minimum Criteria for the Initiation of Antibiotics in Residents of Long-Term–Care Facilities: Results of a Consensus Conference
  323. The Nature and Frequency of Blood Contacts Among Home Healthcare Workers
  324. Inverse Relation between Disease Severity and Expression of the Streptococcal Cysteine Protease, SpeB, among Clonal M1T1 Isolates Recovered from Invasive Group A Streptococcal Infection Cases
  325. Zanamivir Use During Transmission of Amantadine-Resistant Influenza A in a Nursing Home
  326. Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection
  327. Etiology of community-acquired pediatric viral diarrhea: a prospective longitudinal study in hospitals, emergency departments, pediatric practices and child care centers during the winter rotavirus outbreak, 1997 to 1998
  328. Genetic Relatedness and Superantigen Expression in Group A Streptococcus Serotype M1 Isolates from Patients with Severe and Nonsevere Invasive Diseases
  329. Cigarette Smoking and Invasive Pneumococcal Disease
  330. A Comparison of Model-Building Strategies for Lower Respiratory Tract Infection in Long-Term Care
  331. Prevention of Neural-Tube Defects
  332. CLINICAL UTILITY OF QUANTITATIVE CYTOMEGALOVIRUS VIRAL LOAD DETERMINATION FOR PREDICTING CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1
  333. Molecular Characterization of a Nosocomial Outbreak of Human Respiratory Syncytial Virus on an Adult Leukemia/Lymphoma Ward
  334. Two-year survey of Alberta laboratories processing of antenatal group B streptococcal (GBS) screening specimens: implications for GBS screening programs
  335. Risk Factors for Pneumonia and Other Lower Respiratory Tract Infections in Elderly Residents of Long-term Care Facilities
  336. Decreased Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada
  337. Influenza Vaccination in Long-Term–Care Facilities: Structuring Programs for Success
  338. Practical approach to the identification of clinically relevant Enterococcus species
  339. Clinical Experience with 20 Cases of Group A Streptococcus Necrotizing Fasciitis and Myonecrosis: 1995 to 1997
  340. Clinical Experience with 20 Cases of Group A Streptococcus Necrotizing Fasciitis and Myonecrosis: 1995 to 1997
  341. Control of Transmission of Vancomycin-Resistant Enterococcus faecium in a Long-Term–Care Facility
  342. Intravenous Immunoglobulin Therapy for Streptococcal Toxic Shock Syndrome—A Comparative Observational Study
  343. Elevated Serum Cytokines Are Associated with Cytomegalovirus Infection and Disease in Bone Marrow Transplant Recipients
  344. Skin and soft tissue infection
  345. The rapid emergence of a new strain of MRSA in Ontario: Laboratory implications
  346. The use of Streptococcus pneumoniae nasopharyngeal isolates from healthy children to predict features of invasive disease
  347. Effect of Cytomegalovirus Infection on 1‐Year Mortality Rates Among Recipients of Allogeneic Bone Marrow Transplants
  348. Varying Titers of Neutralizing Antibodies to Streptococcal Superantigens in Different Preparations of Normal Polyspecific Immunoglobulin G: Implications for Therapeutic Efficacy
  349. Can pregnant women obtain their own specimens for group B streptococcus? A comparison of maternal versus physician screening. The Mount Sinai GBS Screening Group
  350. Invasive Infections Due to a Fish Pathogen, Streptococcus iniae
  351. Population-Based Surveillance for Group A Streptococcal Necrotizing Fasciitis: Clinical Features, Prognostic Indicators, and Microbiologic Analysis of Seventy-Seven Cases
  352. Invasive Group A Streptococcal Infections
  353. Novel Superantigens from Streptococcal Toxic Shock Syndrome Streptococcus pyogenes Isolates
  354. Superantigenic Activity Produced by Group A Streptococcal Isolates is Neutralized by Plasma from IVIG-Treated Streptococcal Toxic Shock Snydrome Patients
  355. Invasive Group A Streptococcal Infections in Ontario, Canada
  356. Tuberculosis Surveillance Practices in Long-Term Care Institutions
  357. Tuberculosis Surveillance Practices in Long-Term Care Institutions
  358. Pharmacoeconomic Analysis of Empirical Therapy with Ceftazidime Alone or Combination Antibiotics for Febrile Neutropenia in Cancer Patients
  359. Influenza and Pneumococcal Vaccination and Tuberculin Skin Testing Programs in Long-Term Care Facilities: Where Do We Stand?
  360. Influenza and Pneumococcal Vaccination and Tuberculin Skin Testing Programs in Long-Term Care Facilities: Where Do We Stand?
  361. HIV-Associated Lymphoma of the Gastrointestinal Tract: The University of Toronto AIDS-Lymphoma Study Group Experience
  362. Diagnosis of Whipple's Disease by Molecular Analysis of Peripheral Blood
  363. The Use of Molecular Typing Techniques in the Epidemiologic Investigation of Resistant Enterococci
  364. The Use of Molecular Typing Techniques in the Epidemiologic Investigation of Resistant Enterococci
  365. Human Immunodeficiency Virus Transmission Between Surgeons and Patients in Orthopaedic Surgery
  366. Recent advances in the management of infections in cancer patients
  367. A Cluster of Surgical Wound Infections Due to Unrelated Strains of Group a Streptococci
  368. Reliability of interpretation of tuberculin testing in the elderly: Implications for practice
  369. Incorporating variations in the quality of individual randomized trials into meta-analysis
  370. Mechanisms of Glove Tears and Sharp Injuries Among Surgical Personnel
  371. Effect of an Automated Sink on Handwashing Practices and Attitudes in High-Risk Units
  372. Effect of an Automated Sink on Handwashing Practices and Attitudes in High-Risk Units
  373. Definitions of infections
  374. Identification and management of salmonellosis in a newborn nursery
  375. Antibiotic prescribing patterns in long-term care facilities (LTCFs)
  376. Body temperature variation in elderly residents of long-term care facilities (LTCFs)
  377. Definitions of infection for surveillance in long-term care facilities
  378. Epidemiology of Needlestick Injuries in House Officers
  379. Surveillance for Quality Assessment: II. Surveillance for Noninfectious Processes: Back to Basics
  380. Surveillance for Quality Assessment: II. Surveillance for Noninfectious Processes: Back to Basics
  381. The buffering capacity of the internal phase of thylakoids and the magnitude of the pH changes inside under flashing light
  382. CALIBRATION OF FLASH INDUCED pH CHANGES INSIDE THYLAKOIDS AND KINETIC RESOLUTION OF PROTON EJECTION AND CONSUMPTION
  383. Terminal Cross-linking of DNA Catalyzed by an Enzyme System Containing DNA Ligase, DNA Polymerase, and Exonuclease of Bacteriophage T7
  384. The Effect of Universal Influenza Immunization on Mortality and Health Care Use